Compare CRBU & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBU | VYGR |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.9M | 194.0M |
| IPO Year | 2021 | 2015 |
| Metric | CRBU | VYGR |
|---|---|---|
| Price | $1.82 | $3.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $10.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.2M | 482.8K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.37 | $71.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $2.65 |
| 52 Week High | $3.53 | $5.55 |
| Indicator | CRBU | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 50.54 |
| Support Level | $1.71 | $3.73 |
| Resistance Level | $2.11 | $4.43 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 38.03 | 56.88 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.